메뉴 건너뛰기
Annals of Pharmacotherapy
Volumn 43, Issue 1, 2009, Pages 114-117
Dosing nomograms: Silos on a slope
Author keywords

Anticoagulation; Dosing; Nomograms
Indexed keywords

ARGATROBAN; ENOXAPARIN; THROMBIN INHIBITOR; DRUG;
EID: 58549099265     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L526     Document Type: Note
Times cited : (2)
References (11)
  • 1
    • 58549089194 scopus 로고    scopus 로고
    • Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia
    • Epub 6 Jan, DOI 10.1345.aph/1L213
    • Ansara AJ, Arif S, Warhurst RD. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2009;43:9-18. Epub 6 Jan 2009. DOI 10.1345.aph/1L213
    • (2009) Ann Pharmacother 2009 , vol.43 , pp. 9-18
    • Ansara, A.J.1    Arif, S.2    Warhurst, R.D.3
  • 2
    • 58549108988 scopus 로고    scopus 로고
    • Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia
    • Epub 30 Dec, DOI 10.1345.aph/1L224
    • Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009;43:19-27. Epub 30 Dec 2008. DOI 10.1345.aph/1L224
    • (2008) Ann Pharmacother 2009 , vol.43 , pp. 19-27
    • Keegan, S.P.1    Gallagher, E.M.2    Ernst, N.E.3    Young, E.J.4    Mueller, E.W.5
  • 3
    • 58549086848 scopus 로고    scopus 로고
    • Product information. Argatroban (argatroban). Research Triangle Park, NC: GlaxoSmithKline, April 2008
    • Product information. Argatroban (argatroban). Research Triangle Park, NC: GlaxoSmithKline, April 2008
  • 4
    • 0037765191 scopus 로고    scopus 로고
    • Argatroban dosing in patients with heparin-induced thrombocytopenia
    • DOI 10.1345/aph.1C443
    • Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:970-5. DOI 10.1345/aph.1C443
    • (2003) Ann Pharmacother , vol.37 , pp. 970-975
    • Verme-Gibboney, C.N.1    Hursting, M.J.2
  • 5
    • 34047241060 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia: A review of treatment options and special considerations
    • Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: a review of treatment options and special considerations. Pharmacotherapy 2007;27:564-87.
    • (2007) Pharmacotherapy , vol.27 , pp. 564-587
    • Dager, W.E.1    Dougherty, J.A.2    Nguyen, P.H.3    Militello, M.A.4    Smythe, M.A.5
  • 6
    • 4143113354 scopus 로고    scopus 로고
    • Comparing direct thrombin inhibitors using aPTT, ecarin clotting times and thrombin inhibitor management testing
    • Epub 6 Jul, DOI 10.1345/aph.1D565
    • Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times and thrombin inhibitor management testing. Ann Pharmacother 2004;38:1383-8. Epub 6 Jul 2004. DOI 10.1345/aph.1D565
    • (2004) Ann Pharmacother 2004 , vol.38 , pp. 1383-1388
    • Gosselin, R.C.1    King, J.H.2    Janatpour, K.A.3    Dager, W.E.4    Larkin, E.C.5    Owings, J.T.6
  • 7
    • 18944399168 scopus 로고    scopus 로고
    • Effect of argatroban on the activated partial thromboplastin time: A comparison of 21 commercial reagents
    • Frances JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 2005;16:251-7.
    • (2005) Blood Coagul Fibrinolysis , vol.16 , pp. 251-257
    • Frances, J.L.1    Hursting, M.J.2
  • 8
    • 33645694284 scopus 로고    scopus 로고
    • Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction
    • Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006;26:452-60.
    • (2006) Pharmacotherapy , vol.26 , pp. 452-460
    • Kiser, T.H.1    Fish, D.N.2
  • 9
    • 51849162822 scopus 로고    scopus 로고
    • Safety, efficacy, and dosing requirement of bivalirudin in patients with heparin-induced thrombocytopenia
    • Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirement of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008;28:1115-24.
    • (2008) Pharmacotherapy , vol.28 , pp. 1115-1124
    • Kiser, T.H.1    Burch, J.C.2    Klem, P.M.3    Hassell, K.L.4
  • 10
    • 33645686878 scopus 로고    scopus 로고
    • Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia
    • Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006;26:461-8.
    • (2006) Pharmacotherapy , vol.26 , pp. 461-468
    • Dang, C.H.1    Durkalski, V.L.2    Nappi, J.M.3
  • 11
    • 45949103154 scopus 로고    scopus 로고
    • Warkentin TE, Greinacher A, Koster A, Lincoff AM. Chest treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133(6 suppl):340S-80S.
    • Warkentin TE, Greinacher A, Koster A, Lincoff AM. Chest treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133(6 suppl):340S-80S.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.